Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
ViiV Healthcare, the global specialist HIV company majority-owned by UK pharma major GlaxoSmithKline, today announced results from the Phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection. 27 October 2017
Germany’s Bayer saw its shares fall as much as 3.5% to 110.85 euros this morning, after the company released its third-quarter 2017 financial results, which showed that sales were dragged down by its consumer health business. 26 October 2017
Despite reporting significant sales growth for the third-quarter of 2017, French biopharma firm Ipsen saw its shares drop 6.43% to 105.50 euros in morning trading. 26 October 2017
Hot on the heels of Canadian and US marketing approval of its shingles vaccine Shingrix, UK pharma major GlaxoSmithKline late yesterday received a follow-on boost for its product with a US recommendation as the preferred shingles vaccine from the committee responsible for vaccination policy in the USA. 26 October 2017
There did not appear too much to worry investors in the third-quarter financial results of the UK’s biggest pharma company, GlaxoSmithKline, as they were presented on Tuesday. 26 October 2017
Pharmaceutical event organizer CPhI Worldwide has released its annual report, which features insights and projections from industry figures. 25 October 2017
Basilea Pharmaceutica says that the sales of the antifungal Cresemba (isavuconazole) in the USA exceeded the threshold triggering the first sales milestone payment from licensee Astellas Pharma . 25 October 2017
On November 20, the question of which country will host the European Medicines Agency post-Brexit will finally be settled, at the European Council’s General Affairs (Art. 50) meeting. 25 October 2017
Swedish Orphan Biovitrum saw its share rise 4.33% to 122.90 Swedish kronor, after it announced its results for the third quarter 2017, with earnings beating analysts’ expectations. 25 October 2017
Eli Lilly reported revenue and earnings figures for the third quarter of 2017 that narrowly exceeded the expectations of Wall Street analysts on Tuesday. 24 October 2017
Swiss pharma giant Novartis this morning reported that sales for the first quarter of 2017 rose 2% to $12.4 billion, beating the Reuters poll average of $12.2 billion. 24 October 2017
In New Zealand, from November 1, 2017, Ozurdex (dexamethasone implants) will be funded for eligible people with diabetic macular edema (DMO), a serious complication of type 1 and type 2 diabetes that can cause blindness if untreated. 24 October 2017
One year ago, the European Medicines Agency (EMA) became the first regulatory authority to give open access to clinical data submitted by companies in support of their marketing authorization applications. 24 October 2017
A new study comparing the economic impacts of varying contract manufacturing approaches has found that a single-source outsourcing model shortens the drug development cycle, providing sponsors with substantial financial gains from having their products reach the market sooner. 24 October 2017
Bayer has entered into a strategic partnership with the healthcare division of Chinese tech company Alibaba Group, giving the German firm access to large amounts of customer data from the Alibaba platform. 23 October 2017
The US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) for Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection. 23 October 2017